Abbott Laboratories

Yahoo Finance • 2 days ago

Abbott (ABT) Wins FDA Approval for Volt PFA System in AFib Treatment

Abbott Laboratories (NYSE:ABT) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026.Abbott (ABT) Wins FDA Approval for Volt PFA System in AFib Treatment Courtesy of Abbott Labs On December 22, Abbott Laboratories (NYSE:ABT... Full story

Yahoo Finance • 3 days ago

U.S. Embolic Protection Devices Market and Competition Analysis, 2025-2033, Featuring Abbott Laboratories, Allium Medical Solutions, Boston Scientific, Cardinal Health and More

Company Logo Key states, including California and Texas, lead in demand due to advanced healthcare systems and aging populations U.S. Embolic Protection Device MarketU.S. Embolic Protection Device Market Dublin, Dec. 29, 2025 (GLOBE NEW... Full story

Yahoo Finance • 6 days ago

Peter Lynch Detailed Fundamental Analysis - ABT

Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for s... Full story

Yahoo Finance • 8 days ago

Is Fidelity Medical Equipment the Ultimate "Forever Fund" for Health Care Investors?

Key Points The health care industry took a trillion-dollar body blow from federal spending cuts in 2025, but still rose by a double-digit percentage. Its resilience comes thanks to unstoppable demographic trends in a must-have industry. O... Full story

Yahoo Finance • 9 days ago

Is Abbott Laboratories Attractively Priced After Recent Share Price Gains And DCF Concerns?

If you have been wondering whether Abbott Laboratories is still a buy at around $125 a share, you are not alone. This is exactly the kind of stock where valuation really matters. Despite slipping about 2.5% over the last week and 2.3% over... Full story

Yahoo Finance • 9 days ago

Abbott Wins FDA Clearance for Volt

This article first appeared on GuruFocus. Abbott Laboratories (NYSE:ABT) picked up a meaningful win Monday after the FDA approved its Volt Pulsed Field Ablation system for treating atrial fibrillation, a condition that affects millions of... Full story

Yahoo Finance • 10 days ago

Abbott Wins FDA Approval For Volt Heart Rhythm Treatment

(RTTNews) - Abbott (ABT) announced on Monday that the U.S. Food and Drug Administration has approved its Volt Pulsed Field Ablation (PFA) system for treating atrial fibrillation, paving the way for commercial use of the device in the Unite... Full story

Yahoo Finance • 10 days ago

Abbott's Volt™ Pulsed Field Ablation System Receives FDA Approval to Treat Patients with Atrial Fibrillation

Abbott's Volt™ PFA System, the latest generation of cardiac ablation technology, is designed for people battling heart rhythm disorders such as atrial fibrillation (AFib) Pulsed field ablation – or PFA – is a minimally invasive procedure t... Full story

Yahoo Finance • 10 days ago

Investors in Abbott Laboratories (NYSE:ABT) have seen returns of 27% over the past five years

The main point of investing for the long term is to make money. But more than that, you probably want to see it rise more than the market average. But Abbott Laboratories (NYSE:ABT) has fallen short of that second goal, with a share price... Full story

Yahoo Finance • 13 days ago

Wonderinterest Assessed Investments in Top Sustainable Global Companies

LIMASSOL, Cyprus, Dec. 19, 2025 /PRNewswire/ -- Wonderinterest Trading, a regulated investment firm operating across global markets, assessed sustainability-focused investing by analyzing the leading companies as presented in the Dow Jones... Full story

Yahoo Finance • 14 days ago

Abbott (ABT): Assessing Valuation After New Regulatory Wins for Its Pediatric Heart Device Innovation

Abbott Laboratories (ABT) just picked up fresh FDA clearance and a CE Mark for its Amplatzer Piccolo Delivery System, a pediatric heart device upgrade that could quietly strengthen both its structural heart franchise and its long term grow... Full story

Yahoo Finance • 14 days ago

Can Abbott Laboratories (ABT) Deliver Resilient Returns in the Long Term?

Parnassus Investments, an investment management firm, released its “Parnassus Value Equity Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund focuses on owning a concentrated portfolio of U.S. l... Full story

Yahoo Finance • 14 days ago

Abbott's Amplatzer Piccolo™ Delivery System Receives FDA Clearance and CE Mark to Optimize Procedures for Premature Babies With a Hole in the Heart

First and only delivery system designed specifically for premature infants with a patent ductus arteriosus (PDA), a life-threatening opening in their heart New delivery system enables precise placement of Abbott's Amplatzer Piccolo Occlude... Full story

Yahoo Finance • 14 days ago

2 Dividend Stocks to Buy for 2026 and Beyond

Key Points CVS Health is slowly righting the ship after several challenging years. Abbott Laboratories' strong business should improve thanks to an acquisition. Both healthcare leaders have attractive long-term prospects and solid dividen... Full story

Yahoo Finance • 15 days ago

How The Abbott Takeover Is Rewriting Exact Sciences Story And Valuation

Exact Sciences stock now sits at the center of a tightening deal spread, with our fair value estimate holding steady near $103.67 per share. This closely tracks the proposed $105 takeout price even as the discount rate edges up to 7.27 and... Full story

Yahoo Finance • 15 days ago

Abbott Laboratories (NYSE:ABT) Shareholders Will Want The ROCE Trajectory To Continue

What are the early trends we should look for to identify a stock that could multiply in value over the long term? One common approach is to try and find a company with returns on capital employed (ROCE) that are increasing, in conjunction... Full story

Yahoo Finance • 15 days ago

Blood Glucose Monitor Market Set to Reach USD 25.4 Billion by 2030 with a CAGR of 9.1%

Company Logo The global blood glucose monitor market is set to expand from USD 16.5 billion in 2025 to USD 25.4 billion by 2030, growing at a CAGR of 9.1%. This growth is fueled by the increasing prevalence of diabetes, a rising geriatric... Full story

Yahoo Finance • 15 days ago

Should Competitive Pressure In Vascular Closure Devices Prompt a Reassessment by Haemonetics (HAE) Investors?

Earlier this week, Needham downgraded Haemonetics from “Buy” to “Hold,” pointing to intensifying competition in vascular closure devices from Abbott and Cordis and warning that this could weigh on the company’s Interventional Technologies... Full story

Yahoo Finance • 18 days ago

Immuno-oncology Clinical Trials Market Projected to Reach USD 23.63 Billion by 2032 at a CAGR of 12.37% - SNS Insider

Austin, Texas, Dec. 14, 2025 (GLOBE NEWSWIRE) -- According to SNS Insider, The Immuno-oncology Clinical Trials Market sizewas valued at USD 8.30 billion in 2023 and is expected to reach USD 23.63 billion by 2032, growing at a CAGR of 12.... Full story

Yahoo Finance • 18 days ago

Start the New Year Off With Passive Income: 3 Dividend Kings to Buy Now

Key Points Dividend stocks may boost your portfolio during any market environment. These particular companies have shown their commitment to dividend payments and growth over time.10 stocks we like better than Coca-Cola › When the market... Full story